Mary Dixon

Mary Dixon is a procurement specialist focused exclusively on research and development in biotechnology, with a clear mandate to advance scientific innovation through strategic contracting. She manages the full lifecycle of acquisitions for complex biotech R&D services, including preclinical studies, biomarker discovery, genetic sequencing technologies, and translational research support. Her work directly supports the agency’s mission to accelerate breakthroughs in public health and life sciences by ensuring timely, compliant, and technically sound contract awards. She interfaces closely with scientific stakeholders to translate research objectives into precise statement of work requirements and evaluation criteria. Her contractor relationships are centered on specialized biotechnology firms with proven expertise in molecular biology, cell therapy development, and bioinformatics platforms. While no single vendor dominates her portfolio, she consistently engages with mid-sized and emerging firms possessing deep technical capabilities in recombinant protein production, CRISPR-based platforms, and high-throughput screening. Her contracting approach emphasizes performance-based outcomes, rigorous technical evaluation, and adherence to Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) standards. Mary Dixon maintains a strong preference for non-set-aside acquisitions, with 100% of her awards issued under full and open competition. This reflects a deliberate strategy to prioritize technical merit and scientific capability over socioeconomic classifications, ensuring the highest quality outcomes for mission-critical biotech research. While she does not routinely utilize 8(a), HUBZone, or SDVOSB set-asides, her process remains transparent and equitable, open to all qualified offerors regardless of size or status. Her primary NAICS code, 541714, underscores her deep specialization in biotechnology R&D. She procures services ranging from gene synthesis and antibody development to clinical trial design support and regulatory strategy consulting. Her domain expertise lies at the intersection of life sciences and federal procurement, ensuring that contracts align with evolving scientific standards and federal research priorities.